Photo from Paolo Tarantino/Twitter
Oct 19, 2023, 18:39
Paolo Tarantino: The BEGONIA ph1/2 trial ages like good wine
Quoting Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, on X/Twitter:
“The BEGONIA ph1/2 trial ages like good wine. At SABCS22, with 7 months of follow up, Dato-DXd+durva had shown an ORR of 73% for 1L TNBC. In the updated abstract at ESMO23, ORR increased to 79%, median PFS exceeded one year (13.8 months). Only 3 cases of ILD (max G2).”
Source: Paolo Tarantino/Twitter.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19